To own Ultragenyx Pharmaceutical, you need to believe the rare disease portfolio, including UX111, can support a shift from heavy cash burn to a more self-funding model. According to AnimalDoctorKwon, an investor in the Simply Wall St Community, the big concern is whether a multi-product lineup can offset what they see as structural inefficiencies in the commercial setup.
Management now talks about sustained profitability in 2027, backed by cost cuts and a strong cash position, which directly addresses that concern. In the short term, a key swing factor is whether recent gene therapy launches and UX111 progress convert into usable revenue. The biggest risk remains execution on high fixed cost infrastructure with limited cash runway and negative equity.
The UX111 regulatory progress in the UK and Europe appears most connected to this week’s conference appearances. A newly accepted MHRA application and EMA review give Ultragenyx Pharmaceutical something concrete to walk through with investors who are weighing the turnaround story against past losses of US$524 million on US$730 million of revenue.
UX111 now sits alongside FAYUVI and GENGLYCOS as part of the gene therapy lineup that management links to potential 2027 profitability. That positions these conferences as checkpoints on how far the business has moved from what AnimalDoctorKwon calls a cash incinerating treadmill to a platform that can service manufacturing, supply chain and debt without relying on frequent fresh capital.
On AnimalDoctorKwon’s numbers, the fair value is estimated at US$26.00 per share, based on a 5.9% annual revenue growth profile and a future profit margin assumption of 18.0% once Ultragenyx Pharmaceutical stabilizes its cost structure and scales its rare disease and gene therapy portfolio.
Uncover why Ultragenyx Pharmaceutical's fair value indicates a 47% potential upside to its current price, a discount that could close quickly.
One big swing factor the more pessimistic analysts keep coming back to is payer pushback on Ultragenyx Pharmaceutical’s high priced gene therapies. Before this UX111 news, the lowest forecasts were built around revenue climbing about 14.1% a year yet still not reaching profitability, with earnings projected at US$169.5 million only by 2029. Those estimates came with some of the group not even expecting positive earnings at that point. You can treat this UX111 review and the upcoming London conferences as fresh data points that might either ease those worries or reinforce them, so it makes sense to compare these bearish assumptions with your own view and explore several different angles on the story.
Explore 4 other Ultragenyx Pharmaceutical fair value estimates, including one that suggests it could be worth just $24.80!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so consider going with your instincts.
If Ultragenyx Pharmaceutical has sharpened your thinking on risk, reward and timelines, it can help to line it up against other opportunities with different profiles on quality, volatility and income.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com